Title :

IMPELLA® or Extracorporeal Membrane Oxygenation for Left Ventricular Dominant Refractory Cardiogenic Shock

Author(s) :

Schurtz, Guillaume [Auteur]
Institut Coeur Poumon [CHU Lille]
Rousse, Natacha [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Coeur Poumon [CHU Lille]
Saura, Ouriel [Auteur]
Institut Coeur Poumon [CHU Lille]
Balmette, Vincent [Auteur]
Institut Coeur Poumon [CHU Lille]
Vincent, Flavien [Auteur]
Institut Coeur Poumon [CHU Lille]
Lamblin, Nicolas [Auteur]
Alliance française pour les essais cliniques cardio-vasculaires - French Alliance for Cardiovascular Trials [FACT]
Institut Coeur Poumon [CHU Lille]
Porouchani, Sina [Auteur]
Institut Coeur Poumon [CHU Lille]
Verdier, Basile [Auteur]
Institut Coeur Poumon [CHU Lille]
Puymirat, Etienne [Auteur]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Robin, Emmanuel [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Coeur Poumon [CHU Lille]
van Belle, Eric [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Coeur Poumon [CHU Lille]
Vincentelli, André [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Coeur Poumon [CHU Lille]
Aissaoui, Nadia [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Delhaye, Cédric [Auteur]
Institut Coeur Poumon [CHU Lille]
Delmas, Clément [Auteur]
Institut des Maladies Métaboliques et Cardiovasculaires [I2MC]
Cosenza, Alessandro [Auteur]
Institut Coeur Poumon [CHU Lille]
Bonello, Laurent [Auteur]
Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research [C2VN]
Mediterranean Association for Research and Studies in Cardiology [MARS cardio]
Juthier, Francis [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Coeur Poumon [CHU Lille]
Moussa, Mouhamed [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Coeur Poumon [CHU Lille]
Lemesle, Gilles [Auteur correspondant]
Alliance française pour les essais cliniques cardio-vasculaires - French Alliance for Cardiovascular Trials [FACT]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Institut Coeur Poumon [CHU Lille]

Journal title :

Journal of clinical medicine

Pages :

759

Publisher :

MDPI

Publication date :

2021-02-14

ISSN :

2077-0383

English keyword(s) :

IMPELLA(®)
extracorporeal membrane oxygenation
mechanical circulatory support
cardiogenic shock

HAL domain(s) :

Sciences du Vivant [q-bio]/Médecine humaine et pathologie

English abstract : [en]

Mechanical circulatory support (MCS) devices are effective tools in managing refractory cardiogenic shock (CS). Data comparing veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and IMPELLA® are however scarce. ...
Show more >Mechanical circulatory support (MCS) devices are effective tools in managing refractory cardiogenic shock (CS). Data comparing veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and IMPELLA® are however scarce. We aimed to assess outcomes of patients implanted with these two devices and eligible to both systems. From 2004 to 2020, we retrospectively analyzed 128 patients who underwent VA-ECMO or IMPELLA® in our institution for refractory left ventricle (LV) dominant CS. All patients were eligible to both systems: 97 patients were first implanted with VA-ECMO and 31 with IMPELLA®. The primary endpoint was 30-day all-cause death. VA-ECMO patients were younger (52 vs. 59.4, p = 0.006) and had a higher lactate level at baseline than those in the IMPELLA® group (6.84 vs. 3.03 mmol/L, p < 0.001). Duration of MCS was similar between groups (9.4 days vs. 6 days in the VA-ECMO and IMPELLA® groups respectively, p = 0.077). In unadjusted analysis, no significant difference was observed between groups in 30-day mortality: 43.3% vs. 58.1% in the VA-ECMO and IMPELLA® groups, respectively (p = 0.152). After adjustment, VA-ECMO was associated with a significant reduction in 30-day mortality (HR = 0.25, p = 0.004). A higher rate of MCS escalation was observed in the IMPELLA® group: 32.3% vs. 10.3% (p = 0.003). In patients eligible to either VA-ECMO or IMPELLA® for LV dominant refractory CS, VA-ECMO was associated with improved survival rate and a lower need for escalation.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011

Source :

Harvested from HAL